pituitary axis comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C221H366N72O67S | Reflects a 44-residue peptide with one N-terminal modification |
| Approximate molecular weight | 5136 Da | Sequence length and single acyl group determine the mass |
| Appearance | White to off-white lyophilized powder | Typical form of a purified synthetic peptide |
| Solubility class | Soluble in water and aqueous buffer | Peptide backbone favors aqueous dissolution |
| Common synonyms | GHRH(1-44) analogue; Egrifta | Descriptive name and approved brand name |
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
==== Biden administration ==== On 13 February 2021, the White House said it had "deep concerns" about both the way the WHO's findings were communicated and the process used to reach them. Mirroring concerns raised by the Trump administration, National Security Advisor Jake Sullivan stated that it was essential that the WHO-convened report be independent and "free from alteration by the Chinese government". On 14 April 2021, the Director of National Intelligence Avril Haines, along with other Biden administration officials, said that they had not ruled out the possibility of a laboratory accident as the origin of the COVID-19 virus. On 26 May 2021, President Joe Biden directed the U.S. intelligence community to produce a report within 90 days on whether the COVID-19 virus originated from human contact with an infected animal or from an accidental lab leak, stating his national security staff said there is insufficient evidence to determine either hypothesis to be more likely. On 26 August 2021, the Office of the Director of National Intelligence released an unclassified summary of their findings, with the main point being that the report remained inconclusive as to the origin of the virus, with intelligence agencies divided on the question. The report also concluded that the virus was most likely not genetically engineered, and that China had no foreknowledge of the virus prior to the outbreak.
The app's operator suggested in court documents pertaining to its lawsuit to overturn the order that the retaliation was also for a ticket reservation prank waged by some users of the video platform that depressed attendance for a campaign rally he held in Tulsa, Oklahoma, that June. The executive order was blocked by federal courts in two separate cases on grounds that the sanctions likely violated IEEPA's informational materials exemption (under the Berman Amendment) and First Amendment protections applying to users of the apps. In February 2026, the Supreme Court held that the IEEPA did not authorize the president to set tariffs in Learning Resources, Inc. v. Trump. This decision reversed the tariffs implemented by Trump under IEEPA during his second term. Consequently, U.S. Customs established a new process—the Consolidated Administration & Processing of Entries (CAPE) system—to refund importers for voided IEEPA duties.
Chitosan is produced commercially by deacetylation of chitin, which is the structural element in the exoskeleton of crustaceans (such as crabs and shrimp) and cell walls of fungi. A common method for obtaining chitosan is the deacetylation of chitin using sodium hydroxide in excess as a reagent and water as a solvent. The reaction follows first-order kinetics though it occurs in two steps; the activation energy barrier for the first stage is estimated at 48.8 kJ·mol−1 at 25–120 °C (77–248 °F) and is higher than the barrier to the second stage.
Sources: en.wikipedia.org
Birches native to Eurasia include Betula albosinensis – Chinese red birch (northern + central China) Betula alnoides – alder-leaf birch (China, Himalayas, northern Indochina) Betula ashburneri – (Bhutan, Tibet, Sichuan, Yunnan Provinces in China) Betula baschkirica – (eastern European Russia) Betula bomiensis – (Tibet) Betula browicziana – (Turkey and Georgia) Betula buggsii – (China) Betula calcicola – (Sichuan + Yunnan Provinces in China) Betula celtiberica – (Spain and Portugal) Betula chichibuensis – (Chichibu region of Japan) Betula chinensis – Chinese dwarf birch (China, Korea) Betula coriaceifolia – (Uzbekistan) Betula corylifolia – (Honshu Island in Japan) Betula costata – (northeastern China, Korea, Primorye region of Russia) Betula cylindrostachya – (Himalayas, southern China, Myanmar) Betula dahurica – (eastern Siberia, Russian Far East, northeastern China, Mongolia, Korea, Japan) Betula delavayi – (Tibet, southern China) Betula ermanii – Erman's birch (eastern Siberia, Russian Far East, northeastern China, Korea, Japan) Betula falcata – (Tajikistan) Betula fargesii – (Chongqing + Hubei Provinces in China) Betula fruticosa – (eastern Siberia, Russian Far East, northeastern China, Mongolia, Korea, Japan) Betula globispica – (Honshu Island in Japan) Betula gmelinii – (Siberia, Mongolia, northeastern China, Korea, Hokkaido Island in Japan) Betula grossa – Japanese cherry birch (Japan) Betula gynoterminalis – (Yunnan Province in China) Betula honanensis – (Henan Province in China) Betula humilis or Betula kamtschatica – Kamchatka birch platyphylla (northern + central Europe, Siberia, Kazakhstan, Xinjiang, Mongolia, Korea) Betula insignis – (southern China) Betula karagandensis – (Kazakhstan) Betula klokovii – (Ukraine) Betula kotulae – (Ukraine) Betula luminifera – (China) Betula maximowicziana – monarch birch (Japan, Kuril Islands) Betula medwediewii – Caucasian birch (Turkey, Iran, Caucasus) Betula megrelica – (Republic of Georgia) Betula microphylla – (Siberia, Mongolia, Xinjiang, Kazakhstan, Kyrgyzstan, Uzbekistan) Betula nana – dwarf birch (northern + central Europe, Russia, Siberia, Greenland, Northwest Territories of Canada)) Betula pendula – silver birch (widespread in Europe and northern Asia; Morocco; naturalized in New Zealand and scattered locations in US + Canada) Betula platyphylla – (Betula pendula var. platyphylla) – Siberian silver birch (Siberia, Russian Far East, Manchuria, Korea, Japan, Alaska, western Canada) Betula potamophila – (Tajikistan) Betula potaninii – (southern China) Betula psammophila – (Kazakhstan) Betula pubescens – downy birch, also known as white, European white or hairy birch (Europe, Siberia, Greenland, Newfoundland; naturalized in scattered locations in US) Betula raddeana – (Caucasus) Betula saksarensis – (Khakassiya region of Siberia) Betula saviczii – (Kazakhstan) Betula schmidtii – (northeastern China, Korea, Japan, Primorye region of Russia) Betula sunanensis – (Gansu Province of China) Betula szechuanica – (Betula pendula var. szechuanica)—Sichuan birch (Tibet, southern China) Betula tianshanica – (Kazakhstan, Kyrgyzstan, Tajikistan, Uzbekistan, Xinjiang, Mongolia) Betula utilis – Himalayan birch (Afghanistan, Central Asia, China, Tibet, Himalayas) Betula wuyiensis – (Fujian Province of China) Betula zinserlingii – (Kyrgyzstan) Note: many American texts have B. pendula and B. pubescens confused, though they are distinct species with different chromosome numbers.
=== Hospital fomites === For humans, common hospital fomites are skin cells, hair, clothing, and bedding. Fomites are associated particularly with hospital-acquired infections (HAIs), as they are possible routes to pass pathogens between patients. Stethoscopes and neckties are common fomites associated with health care providers. It worries epidemiologists and hospital practitioners because of the growing selection of microbes resistant to disinfectants or antibiotics (so-called antimicrobial resistance phenomenon). Basic hospital equipment, such as IV drip tubes, catheters, and life support equipment, can also be carriers, when the pathogens form biofilms on the surfaces. Careful sterilization of such objects prevents cross-infection. Used syringes, if improperly handled, are particularly dangerous fomites.
Members of Generation Z are anxious to pick majors that teach them marketable skills, with an overwhelming majority consider job preparation to be the point of college. A 2018 Gallup poll on over 32,000 university students randomly selected from 43 schools from across the United States found that just over half (53%) of them thought their chosen major would lead to gainful employment. STEM students expressed the highest confidence (62%) while those in the liberal arts were the least confident (40%). Just over one in three thought they would learn the skills and knowledge needed to become successful in the workplace. While the number of students majoring in the humanities has fallen significantly, those in science, technology, engineering, and mathematics, or STEM, have risen sharply. While about half of STEM graduates work in non-STEM jobs, people with collegiate STEM training still tend to earn more, regardless of whether or not their job is STEM-related or not. By the late 2010s, the historical trend of men being more likely to have higher education has reversed. Women are now more likely to enroll in university than men, a trend accelerated by the COVID-19 pandemic. By the end of the 2020–21 academic year, 59.5% of university students were women. This growing sex gap has been growing for four decades in the United States in parallel with other countries of middle to high income. Among those who attend college or university, women are more likely then men to graduate with a degree within six years.
Sources: en.wikipedia.org
=== Regulation of intracellular signaling pathways === TGA1 also regulates intracellular signaling pathways that control tumor-associated behaviors. In retinoblastoma, ITGA1 promotes proliferation, migration, and colony formation through the activation of STAT3 signaling. ITGA1 inhibition decreases STAT3 expression, phosphorylated STAT3 activity, STAT3 nuclear localization, and focal adhesion kinase (FAK) signaling. Restoring STAT3 activity partially recovers the effects of ITGA1 suppression. Transcriptomic analysis of ITGA1-inhibited retinoblastoma cells showed altered regulation of genes involved in focal adhesion, ECM-receptor interactions, integrin signaling, and JAK-STAT pathways, indicating that ITGA1 works as a regulator of multiple signaling networks.
With alprazolam, a short-acting benzodiazepine, taken for eight weeks, 65% of patients experienced significant rebound anxiety. To some degree, these older benzodiazepines are self-tapering. The benzodiazepines diazepam and oxazepam have been found to produce fewer withdrawal reactions than alprazolam, temazepam, or lorazepam. Factors that determine the risk of psychological dependence or physical dependence and the severity of the benzodiazepine withdrawal symptoms during dose reduction of alprazolam include: dosage used, length of use, frequency of dosing, personality characteristics of the individual, previous use of cross-dependent/cross-tolerant drugs (alcohol or other sedative-hypnotic drugs), current use of cross-dependent/-tolerant drugs, use of other short-acting, high-potency benzodiazepines, and method of discontinuation.
Chikungunya vaccines are vaccines intended to provide acquired immunity against the chikungunya virus. As of 2025, two vaccines have been licensed in some countries. These are Ixchiq, a live attenuated vaccine from Valneva, and Vimkunya manufactured by Bavarian Nordic which utilises virus-like particle technology. The most commonly reported side effects of Ixchiq include tenderness at the injection site, as well as headache, fatigue, muscle pain, joint pain, fever, and nausea. However the license for Ixchiq has been suspended or restricted in some countries due to the risk of severe side effects, particularly in older people.
Sources: en.wikipedia.org
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.
It binds the growth hormone-releasing hormone receptor on anterior pituitary cells. Activation of that receptor promotes synthesis and release of growth hormone. The effect propagates through the growth hormone and insulin-like growth factor 1 axis.
Native GHRH is cleared quickly by peptidases, which limits how long it can stimulate its receptor. The added group hinders one of the primary cleavage enzymes. The practical consequence is a longer period of receptor activity per dose.
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.